Phoslo

PhosLo® consists of the mineral calcium acetate. It is an orally given phosphate binder used in patients with End Stage Renal Disease (ESRD). When taken with meals it combines with dietary phosphate in order for the body to eliminate it without absorbing it. High phosphate levels lead to hyperphosphatemia which can result in a myriad of problems. Serum calcium levels should be checked frequently when on PhosLo®. Patients with hypercalcemia should not take PhosLo® and no other calcium supplements should be taken with PhosLo®. Side effects can include hypercalcemia, nausea, and itching.

Additional recommended knowledge

Guide to balance cleaning: 8 simple steps

How to quickly check pipettes?

Correct Test Weight Handling Guide: 12 Practical Tips

History

PhosLo® was owned by Nabi Biopharmaceuticals until late 2006 when it and its related assests was sold to the US subsidiary of Fresenius Medical Care. As of November 14, 2006 Nabi stopped distributing PhosLo®.

References

1. http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info+2007+01+23

2. http://www.nabi.com/products/product.php?id=1

3. http://bioflorida.com/node/196